Drug intelligence / Profile preview

Huanghou Zhixie Diwan

Development stage: Phase 2
Lead developer: Shanghai Leiyunshang Pharmaceutical
Administration: Oral

Overview

Huanghou Zhixie Diwan is a Traditional Chinese Medicine (TCM) product developed by Lei Yunshang Group for the treatment of irritable bowel syndrome with diarrhea (IBS-D), specifically targeting the 'Large Intestinal Damp-heat' syndrome. It is formulated as dripping pills (diwan), a dosage form designed for rapid dissolution and absorption. The drug is currently in Phase II clinical development to evaluate its efficacy and safety in reducing diarrhea and abdominal pain associated with IBS-D. As a TCM formulation, it likely contains multiple botanical extracts intended to regulate gastrointestinal motility and reduce inflammation in the gut.

Brand names: Huanghou Zhixie Diwan
Other names: Huanghou Zhixie Dripping Pills

Targets

NOS2 (Nitric Oxide Synthase 2)

Beyond the preview

Go deeper on Huanghou Zhixie Diwan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huanghou Zhixie Diwan.

Explore the full profile